trending Market Intelligence /marketintelligence/en/news-insights/trending/rkje3nrjtdfvvz6nkp9nww2 content esgSubNav
In This List

Bio-Path regains Nasdaq compliance

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Bio-Path regains Nasdaq compliance

The Nasdaq Stock Market LLC's listing qualifications department notified Bio-Path Holdings Inc. that it has regained compliance with the exchange's minimum bid price requirement.

The closing bid price of Bio-Path common stock has been at $1.00 per share or more from Feb. 9 through Feb. 23.

The Texas-based cancer drugmaker received the noncompliance notice in September 2017.